Precision medicine is providing new hope to patients and their families in Qatar by utilizing international and local medicine-based evidence with Qatar’s unique genetic profile as the basis for a plethora of studies.
Speaking at the inaugural “Women in Science: The Journey toward Precision Medicine” conference held by Sidra Medicine – a member of Qatar Foundation (QF), Dr. Salha Bujassoum, Senior Medical Oncologist at Hamad Medical Corporation’s (HMC) National Centre for Cancer Care and Research (NCCCR), provided frontline insights into how Qatar’s national research efforts and clinical services have advanced an how collaborative efforts in Qatar are improving survival rates and revolutionizing treatment.
Breast cancer is a leading cause of cancer-related deaths worldwide, and the most common malignancy among women in Qatar, accounting for 31 percent of cancer cases in women. The risk of women in the population developing breast cancer is 56 per 100,000.
Dr. Bujassoum highlighted how researchers at HMC’s NCCCR, Sidra Medicine, Weill Cornell Medicine – Qatar (WCM-Q), a QF partner university, and other research hubs are employing precision medicine to transform the understanding of breast cancer prevention, diagnosis and treatment.
She said: “Precision medicine is a strategy for disease treatment and prevention that considers individual variability in genes, environment, and lifestyle – it’s about using genetic biomarkers to switch from one-size-fits-all treatment to a personalized approach. Biomarkers are very important so we can apply systemic treatment for high-risk patients, and with this we can improve survival. Survival is linked with early diagnosis and also the introduction of targeted treatment early on.”
“Precision medicine aims for optimised tumour response to treatment combined with the preservation of organ function and, thus, quality of life. The concept of an individualized approach is not new in the field of breast cancer; however, recent advances in genomic medicine allowed more personalized approaches,” she added.
A better understanding of breast cancer molecular sub-types is enabling doctors to reduce their reliance on chemotherapy, with its savage side-effects, and instead look to new options such as immunotherapy, which helps the body’s immune system to attack cancer cells, as well as hormone therapy and drugs that directly target the tumour.
Speaking on breast cancer prevention, Dr. Bujassoum described how NCCCR launched its high-risk screening clinic in 2013 to cater to patients with a hereditary predisposition to breast and ovarian cancers, which was expanded in 2016 to manage patients at high risk for other hereditary cancers. “In terms of prevention, we are applying risk reduction strategies not only for the person who has the relevant gene mutation but also members of their families, and we are doing this routinely.”
“The median age of diagnosis for our breast cancer patients is 47 years old and around 30 percent of cases are diagnosed below the age of 40 years; young onset breast cancer is typically a more aggressive disease than that experienced by older women,” she explained.
Dr. Salha emphasised that early diagnosis and better treatment rested on a combination of effective clinical care, education and research.
